Cutaneous adverse reactions resulting from targeted cancer therapies: histopathologic and clinical findings.

[1]  T. Ho,et al.  Characterization of cutaneous adverse events to enfortumab vedotin: A retrospective case-control study , 2022, JAAD international.

[2]  G. Neri,et al.  Dermatological manifestations, management, and care in RASopathies , 2022, American journal of medical genetics. Part C, Seminars in medical genetics.

[3]  M. Araki,et al.  Cutaneous toxicity with suprabasal blisters and dyskeratosis following administration of enfortumab vedotin , 2022, The Journal of dermatology.

[4]  L. Fu,et al.  Targeting Extracellular Signal-Regulated Protein Kinase 1/2 (ERK1/2) in Cancer: An Update on Pharmacological Small-Molecule Inhibitors. , 2022, Journal of medicinal chemistry.

[5]  Xuejiao Han,et al.  BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies , 2022, Journal of Hematology & Oncology.

[6]  B. Akkaya,et al.  Exhaust the exhausters: Targeting regulatory T cells in the tumor microenvironment , 2022, Frontiers in Immunology.

[7]  P. Jänne,et al.  Adagrasib in Non-Small-Cell Lung Cancer. Reply. , 2022, The New England journal of medicine.

[8]  A. Gunderwala,et al.  Mechanism and inhibition of BRAF kinase. , 2022, Current opinion in chemical biology.

[9]  G. Attinà,et al.  BRAF and MEK Targeted Therapies in Pediatric Central Nervous System Tumors , 2022, Cancers.

[10]  T. C. Elebiyo,et al.  Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy. , 2022, Cancer treatment and research communications.

[11]  Bonnie Lee,et al.  Enfortumab Vedotin-Associated Toxic Epidermal Necrolysis-like Toxic Erythema of Chemotherapy. , 2022, The American Journal of dermatopathology.

[12]  K. Nakai,et al.  Qualitative differences in disease-associated MEK mutants reveal molecular signatures and aberrant signaling-crosstalk in cancer , 2022, Nature Communications.

[13]  Y. Fujisawa,et al.  Enfortumab vedotin‐induced cutaneous adverse events manifesting as miliaria‐like eruptions with the presence of keratinocyte apoptosis in clinically intact skin , 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

[14]  M. Tripathi,et al.  PRIDE complex-like skin rash associated with bevacizumab , 2022, BMJ Case Reports.

[15]  Duygu Gulseren,et al.  Phototoxic drug eruption induced by vandetanib used for the treatment of metastatic medullary thyroid cancer , 2022, Anais brasileiros de dermatologia.

[16]  G. Gomatou,et al.  BRAF/MEK inhibition in NSCLC: mechanisms of resistance and how to overcome it , 2022, Clinical and Translational Oncology.

[17]  P. Jänne,et al.  Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. , 2022, The New England journal of medicine.

[18]  Yongjun Dang,et al.  Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review , 2022, Frontiers in Chemistry.

[19]  G. McArthur,et al.  Triplet Therapy in Melanoma — Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies , 2022, Current Oncology Reports.

[20]  Y. Fujisawa,et al.  Keratinocyte apoptosis was present in clinically intact skin in a patient treated with enfortumab vedotin. , 2022, European journal of cancer.

[21]  N. Dupin,et al.  Life-threatening skin reaction with Enfortumab Vedotin: Six cases. , 2022, European journal of cancer.

[22]  Jungsook Cho,et al.  Hedgehog Pathway Inhibitors as Targeted Cancer Therapy and Strategies to Overcome Drug Resistance , 2022, International journal of molecular sciences.

[23]  J. Singh,et al.  Enfortumab Vedotin-Induced Toxic Epidermal Necrolysis: A Rare Fatal Adverse Reaction , 2022, Indian dermatology online journal.

[24]  J. Sunshine,et al.  Calciphylaxis Cutis Associated With Fibroblast Growth Factor Receptor (FGFR) Inhibitor Therapy: A New Challenge , 2022, Cureus.

[25]  A. Axelson,et al.  Severe cutaneous drug toxicity following enfortumab vedotin treatment for metastatic urothelial carcinoma , 2022, JAAD case reports.

[26]  Zhuoling An,et al.  Cutaneous Toxicity Associated With Enfortumab Vedotin: A Real-Word Study Leveraging U.S. Food and Drug Administration Adverse Event Reporting System , 2022, Frontiers in Oncology.

[27]  Jiang Liu,et al.  FDA Approval Summary: Sotorasib for KRAS G12C Mutated Metastatic NSCLC. , 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  A. Nast,et al.  A distinctive bullous skin reaction associated with enfortumab vedotin-ejfv treatment for metastatic urothelial cancer: A case report. , 2021, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[29]  D. Hong,et al.  Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors , 2021, Clinical Cancer Research.

[30]  Y. Doki,et al.  Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors , 2021, Nagoya journal of medical science.

[31]  L. Yıldız,et al.  Vandetanib induced phototoxic reaction progressed to toxic epidermal necrolysis , 2021, Anais brasileiros de dermatologia.

[32]  Yanting Zhang,et al.  Role of Nectin‑4 protein in cancer (Review). , 2021, International journal of oncology.

[33]  D. Ledesma,et al.  Diverse landscape of dermatologic toxicities from small‐molecule inhibitor cancer therapy , 2021, Journal of cutaneous pathology.

[34]  A. Joshua,et al.  Review BRAF inhibition and the spectrum of granulomatous reactions. , 2021, Journal of the American Academy of Dermatology.

[35]  C. Kundu,et al.  Nectin cell adhesion molecule-4 (NECTIN-4): A potential target for cancer therapy. , 2021, European journal of pharmacology.

[36]  S. Jones,et al.  Postmarketing Cases of Enfortumab Vedotin-Associated Skin Reactions Reported as Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis. , 2021, JAMA dermatology.

[37]  Azin Gheymati,et al.  Tyrosine kinase inhibitors-associated pyoderma gangrenosum, a systematic review of published case reports , 2021, Anti-cancer drugs.

[38]  A. Dobry,et al.  Cutaneous reactions with enfortumab vedotin: A case series and review of the literature , 2021, JAAD case reports.

[39]  R. Govindan,et al.  Sotorasib for Lung Cancers with KRAS p.G12C Mutation. , 2021, The New England journal of medicine.

[40]  K. Rieger,et al.  Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sézary Syndrome. , 2021, JAMA dermatology.

[41]  Yan Niu,et al.  Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer. , 2021, European journal of medicinal chemistry.

[42]  Y. Fukai,et al.  Ramucirumab-related Oral Pyogenic Granuloma: A Report of Two Cases , 2021, Internal medicine.

[43]  Jianjun Gao,et al.  Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction , 2021, Frontiers in Oncology.

[44]  L. Requena,et al.  Cutaneous eruption with reactive endothelial atypia due to emerging targeted cancer therapies: Report of two cases with clinico‐pathologic correlation , 2021, Journal of cutaneous pathology.

[45]  R. Sullivan,et al.  Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers , 2021, Investigational New Drugs.

[46]  B. Kaffenberger,et al.  Calciphylaxis associated with the fibroblast growth factor receptor inhibitor erdafitinib , 2020, JAAD case reports.

[47]  B. Kelly,et al.  A rare presentation of enfortumab vedotin–induced toxic epidermal necrolysis , 2020, JAAD case reports.

[48]  L. Heinzerling,et al.  MAPK blockade, toxicities, pathogenesis and management , 2020, Current opinion in oncology.

[49]  Emily Coleman,et al.  Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review). , 2020, Oncology reports.

[50]  R. Novoa,et al.  Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma. , 2020, Journal of the American Academy of Dermatology.

[51]  Daniel Q. Bach,et al.  Sweet syndrome as an adverse reaction to tyrosine kinase inhibitors: A review , 2020, Dermatologic therapy.

[52]  M. Lacouture,et al.  Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines , 2020, The oncologist.

[53]  G. Gibney,et al.  Prevalence of class I–III BRAF mutations among 114,662 cancer patients in a large genomic database , 2020, Experimental biology and medicine.

[54]  Ryanne A. Brown,et al.  Histopathologic Characterization of Mogamulizumab-associated Rash , 2020, The American journal of surgical pathology.

[55]  G. Fabbrocini,et al.  Vismodegib-Induced Alopecia: Trichoscopic and Confocal Microscopy Evaluation , 2020, Skin Appendage Disorders.

[56]  S. Aiba,et al.  Severe eczematoid and lichenoid eruption with full‐thickness epidermal necrosis developing from metastatic urothelial cancer treated with enfortumab vedotin , 2020, The Journal of dermatology.

[57]  R. Botella-Estrada,et al.  Systematic review of BRAF/MEK inhibitors‐induced Severe Cutaneous Adverse Reactions (SCARs) , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[58]  I. Brownell,et al.  BRAF Inhibitors for the Treatment of Papulopustular Eruptions from MAPK Pathway Inhibitors , 2020, American Journal of Clinical Dermatology.

[59]  W. Fang,et al.  PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy , 2020, Translational lung cancer research.

[60]  C. Récher,et al.  Dermatological Toxicities of Bruton’s Tyrosine Kinase Inhibitors , 2020, American Journal of Clinical Dermatology.

[61]  D. Haynes,et al.  Adverse cutaneous reactions to chemotherapeutic drugs. , 2020, Clinics in dermatology.

[62]  M. Sznol,et al.  Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study , 2020, Clinical Cancer Research.

[63]  E. Haynes,et al.  Flexural Exanthema From Enfortumab Vedotin , 2020, Cureus.

[64]  Subashini Gnanendran,et al.  Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors , 2020, Current Treatment Options in Oncology.

[65]  A. Porcaro,et al.  Bladder cancer genomics , 2020, Urologia.

[66]  Jian-Long Miao,et al.  The association between fibroblast growth factor receptor 1 gene amplification and lung cancer: a meta-analysis , 2019, Archives of medical science : AMS.

[67]  Yaping Wang,et al.  Risk of hand-foot skin reaction associated with VEGFR-TKIs: a meta-analysis of 57 randomized controlled trials involving 24956 patients. , 2020, Journal of the American Academy of Dermatology.

[68]  Thomas McFarlane,et al.  Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment. , 2020, Annals of palliative medicine.

[69]  R. Dummer,et al.  Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study , 2019, The British journal of dermatology.

[70]  Craig B. Davis,et al.  A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors , 2019, Journal of Immunotherapy for Cancer.

[71]  M. Akiyama,et al.  Atopic dermatitis without serum immunoglobulin E elevation or loss‐of‐function filaggrin gene mutation in a patient with X‐linked agammaglobulinemia , 2019, The Journal of dermatology.

[72]  F. Aubin,et al.  Vitiligo under anti-PD1 therapy is associated with increased survival in melanoma patients. , 2019, Journal of the American Academy of Dermatology.

[73]  Qiaojun He,et al.  Sorafenib-associated hand-foot skin reaction: practical advice on diagnosis, mechanism, prevention, and management , 2019, Expert review of clinical pharmacology.

[74]  T. Ibe,et al.  Development of pyogenic granuloma with strong vascular endothelial growth factor receptor-2 expression during ramucirumab treatment , 2019, BMJ Case Reports.

[75]  G. Sonpavde,et al.  Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma , 2019, Expert opinion on investigational drugs.

[76]  Y. Chida,et al.  Skin ulceration around stoma associated with aflibercept , 2019, BMJ Case Reports.

[77]  K. Muro,et al.  A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors , 2019, Clinical Cancer Research.

[78]  P. Nuciforo,et al.  FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[79]  K. Carson,et al.  Mogamulizumab-Associated Cutaneous Granulomatous Drug Eruption Mimicking Mycosis Fungoides but Possibly Indicating Durable Clinical Response. , 2019, JAMA dermatology.

[80]  Y. Teraki,et al.  Depletion of regulatory FoxP3+ T cells in the pathogenesis of Stevens–Johnson syndrome induced by mogamulizumab , 2019, International journal of dermatology.

[81]  A. Przylipiak,et al.  The expression of the renin-angiotensin-aldosterone system in the skin and its effects on skin physiology and pathophysiology. , 2019, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[82]  N. Kumari,et al.  Epidermal Growth Factor Receptor Mutation Frequency in Squamous Cell Carcinoma and Its Diagnostic Performance in Cytological Samples: A Molecular and Immunohistochemical Study , 2019, World journal of oncology.

[83]  Y. Fujiwara,et al.  Large Skin Ulcer and Delayed Wound Healing around a Colostomy in a Patient with Metastatic Colorectal Cancer Receiving Vascular Endothelial Growth Factor Receptor-2 Inhibitor Therapy , 2019, Case Reports in Oncology.

[84]  A. LaCasce,et al.  Psoriasiform eruptions secondary to phosphoinositide 3-kinase inhibition , 2019, JAAD case reports.

[85]  A. Bode,et al.  AKT as a Therapeutic Target for Cancer. , 2019, Cancer research.

[86]  K. Tamura,et al.  BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[87]  Christopher J. Miller,et al.  NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib , 2018, Journal of cutaneous pathology.

[88]  Yuquan Wei,et al.  Targeting PI3K in cancer: mechanisms and advances in clinical trials , 2019, Molecular Cancer.

[89]  A. Adamson,et al.  Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma. , 2019, Dermatology online journal.

[90]  C. Massone,et al.  Ibrutinib and Pyoderma Gangrenosum in a Patient With B-Cell Chronic Lymphocytic Leukemia. , 2019, The American Journal of dermatopathology.

[91]  J. Ajani,et al.  A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer. , 2019, European journal of cancer.

[92]  Peng Chen,et al.  The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis , 2019, Cutaneous and ocular toxicology.

[93]  Hui-Zi Chen,et al.  Metastatic Calcinosis Cutis Associated With a Selective FGFR Inhibitor. , 2019, JAMA dermatology.

[94]  J. B. Wittel,et al.  Topical diltiazem for ulceration of striae distensae associated with bevacizumab therapy , 2018, Dermatologic therapy.

[95]  Peng Chen,et al.  Systematic review and meta‐analysis of prevalence of dermatological toxicities associated with vemurafenib treatment in patients with melanoma , 2018, Clinical and experimental dermatology.

[96]  Joon-Oh Park,et al.  Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification. , 2019, American journal of translational research.

[97]  Jonathan L Yao,et al.  Xanthogranulomatous reaction to trametinib for metastatic malignant melanoma. , 2018, Cutis.

[98]  B. Zhang,et al.  Adverse events risk associated with regorafenib in the treatment of advanced solid tumors: meta-analysis of randomized controlled trials , 2018, OncoTargets and therapy.

[99]  C. Elmets,et al.  Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. , 2018, The Lancet. Oncology.

[100]  Y. Tokura,et al.  Mogamulizumab‐induced photosensitivity in patients with mycosis fungoides and other T‐cell neoplasms , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[101]  Ravi C. Patel,et al.  Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor , 2018, Journal of cutaneous pathology.

[102]  O. Yamamoto,et al.  CD8+ T cell‐mediated interface dermatitis during combination chemotherapy with mogamulizumab in a patient with adult T‐cell leukaemia/lymphoma , 2018, Clinical and experimental dermatology.

[103]  Shun-Fa Yang,et al.  Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies , 2018, Cancer management and research.

[104]  Qiaojun He,et al.  Vascular endothelial growth factor (VEGF) antibody significantly increases the risk of hand–foot skin reaction to multikinase inhibitors (MKIs): A systematic literature review and meta‐analysis , 2018, Clinical and experimental pharmacology & physiology.

[105]  R. Advani,et al.  Ibrutinib‐associated rash: a single‐centre experience of clinicopathological features and management , 2018, British journal of haematology.

[106]  Manish R. Patel,et al.  First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. , 2017, Cancer discovery.

[107]  P. Espinosa Lara,et al.  Eruptive cherry angiomas developing in a patient treated with ramucirumab , 2017, Acta oncologica.

[108]  D. Ghez,et al.  Ibrutinib-Induced Neutrophilic Dermatosis , 2017, The American Journal of dermatopathology.

[109]  H. Shimizu,et al.  Ramucirumab-induced Multiple Haemangiomas of the Skin: Two Case Reports. , 2018, Acta dermato-venereologica.

[110]  Sung-Hoon Kim,et al.  CNOT2 promotes proliferation and angiogenesis via VEGF signaling in MDA-MB-231 breast cancer cells. , 2018, Cancer letters.

[111]  L. French,et al.  Drug-Induced Pyoderma Gangrenosum: A Review , 2018, American Journal of Clinical Dermatology.

[112]  M. Espié,et al.  Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. , 2017, The Lancet. Oncology.

[113]  Junyan Zhang,et al.  Risk of rash associated with vandetanib treatment in non-small-cell lung cancer patients , 2017, Medicine.

[114]  Adrienne N Choksi,et al.  Granuloma Annulare Secondary to Vemurafenib Therapy for Lung Adenocarcinoma. , 2017, Journal of drugs in dermatology : JDD.

[115]  M. Chren,et al.  Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib , 2017, Journal of the American Academy of Dermatology.

[116]  O. Arrieta,et al.  The Hedgehog-GLI pathway in embryonic development and cancer: implications for pulmonary oncology therapy , 2017, Oncotarget.

[117]  Feng Wang,et al.  Expression of P-EGFR and P-Akt protein in esophageal squamous cell carcinoma and its prognosis , 2017, Oncology letters.

[118]  Frank McCormick,et al.  RAS Proteins and Their Regulators in Human Disease , 2017, Cell.

[119]  Hua Wang,et al.  Pyoderma Gangrenosum in a Patient with X-Linked Agammaglobulinemia , 2017, Annals of dermatology.

[120]  Takeshi Takahashi,et al.  Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia–lymphoma in Japan: interim results of postmarketing all-case surveillance , 2017, International Journal of Hematology.

[121]  J. Fairley,et al.  Lower extremity ecchymotic nodules in a patient being treated with ibrutinib for chronic lymphocytic leukemia , 2017, JAAD case reports.

[122]  Qiaojia Huang,et al.  High expression of EGFR predicts poor survival in patients with resected T3 stage gastric adenocarcinoma and promotes cancer cell survival , 2017, Oncology letters.

[123]  A. Chang,et al.  Reversible cutaneous side effects of vismodegib treatment. , 2017, Cutis.

[124]  Massimo Cristofanilli,et al.  Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application , 2016, Oncotarget.

[125]  C. Perisanidis.  Prevalence of EGFR Tyrosine Kinase Domain Mutations in Head and Neck Squamous Cell Carcinoma: Cohort Study and Systematic Review. , 2017, In vivo.

[126]  D. Cao,et al.  Idelalisib-induced colitis and skin eruption mimicking graft-versus-host disease , 2017, Clinical Journal of Gastroenterology.

[127]  A. Hauschild,et al.  Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma , 2016, The oncologist.

[128]  J. Romaní,et al.  Cutaneous granulomatous panniculitis and sarcoidal granulomatous papular eruption in a patient with metastatic melanoma treated with a BRAF inhibitor , 2016, The Journal of dermatology.

[129]  K. Chanprapaph,et al.  Multikinase Inhibitor-Induced Hand–Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management , 2016, American Journal of Clinical Dermatology.

[130]  A. Henry,et al.  Increased Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma. , 2016, JAMA dermatology.

[131]  T. Kozuki.  Skin problems and EGFR-tyrosine kinase inhibitor. , 2016, Japanese journal of clinical oncology.

[132]  M. Lacouture.  Management of Dermatologic Toxicities Associated With Targeted Therapy , 2016, Journal of the advanced practitioner in oncology.

[133]  B. Bancalari,et al.  Ulcerations on abdominal wound scar associated with aflibercept therapy , 2016, The Journal of dermatology.

[134]  T. Bellón,et al.  Vemurafenib‐induced toxic epidermal necrolysis: possible cross‐reactivity with other sulfonamide compounds , 2016, The British journal of dermatology.

[135]  M. Kodaira,et al.  Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors , 2016, Cancer Chemotherapy and Pharmacology.

[136]  Wei Cheng,et al.  Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells. , 2016, Cancer letters.

[137]  M. Lacouture,et al.  Incidence and risk of hand–foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta‐analysis , 2016, Clinical and experimental dermatology.

[138]  B. Neyns,et al.  Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib. , 2015, Melanoma research.

[139]  B. Dréno,et al.  Early-Onset Vemurafenib-Induced DRESS Syndrome , 2015, Dermatology.

[140]  P. Lorigan,et al.  Dabrafenib and its use in the treatment of metastatic melanoma. , 2015, Melanoma management.

[141]  Jeffrey A Jones,et al.  Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias. , 2015, JAMA oncology.

[142]  J. Hou,et al.  A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. , 2015, Journal of the American Academy of Dermatology.

[143]  P. Foley,et al.  Hair loss and Hedgehog inhibitors: a class effect? , 2015, The British journal of dermatology.

[144]  L. Mortier,et al.  Persistent alopecia induced by vismodegib , 2015, The British journal of dermatology.

[145]  M. Lacouture,et al.  Regorafenib-associated hand–foot skin reaction: practical advice on diagnosis, prevention, and management , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[146]  S. Krishnamoorthy,et al.  Management of regorafenib-related toxicities: a review , 2015, Therapeutic advances in gastroenterology.

[147]  T. Petrella,et al.  Successful switch to dabrafenib after vemurafenib‐induced toxic epidermal necrolysis , 2015, The British journal of dermatology.

[148]  G. Fabbrocini,et al.  Acneiform Rash Induced by EGFR Inhibitors: Review of the Literature and New Insights , 2015, Skin Appendage Disorders.

[149]  Xiaoying Zhang,et al.  Bladder Cancer and Genetic Mutations , 2015, Cell Biochemistry and Biophysics.

[150]  P. LoRusso,et al.  Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways. , 2015, Journal of the American Academy of Dermatology.

[151]  O. Abdel-Rahman,et al.  Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis , 2015, Expert review of anticancer therapy.

[152]  M. Anadkat,et al.  MEK inhibitor-induced dusky erythema: characteristic drug hypersensitivity manifestation in 3 patients. , 2015, JAMA dermatology.

[153]  C. Giurcaneanu,et al.  Cutaneous adverse reactions specific to epidermal growth factor receptor inhibitors , 2015, Journal of medicine and life.

[154]  K. Matsushima,et al.  CCR4 and its ligands: from bench to bedside. , 2015, International immunology.

[155]  M. Goswami,et al.  Reduction of Regulatory T Cells by Mogamulizumab, a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients with Aggressive/Refractory Mycosis Fungoides and Sézary Syndrome , 2014, Clinical Cancer Research.

[156]  Eunyoung Kang,et al.  High EGFR gene copy number predicts poor outcome in triple-negative breast cancer , 2014, Modern Pathology.

[157]  A. Chang,et al.  Two different scenarios of squamous cell carcinoma within advanced Basal cell carcinomas: cases illustrating the importance of serial biopsy during vismodegib usage. , 2014, JAMA dermatology.

[158]  K. Purshouse,et al.  Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma , 2014, The British journal of dermatology.

[159]  Laurens P. Kil,et al.  Targeting Bruton's tyrosine kinase in B cell malignancies , 2014, Nature Reviews Cancer.

[160]  K. Tsai,et al.  Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma , 2014, Journal of cutaneous pathology.

[161]  Michael W Sill,et al.  Improved survival with bevacizumab in advanced cervical cancer. , 2014, The New England journal of medicine.

[162]  E. Raymond,et al.  MEK in cancer and cancer therapy. , 2014, Pharmacology & therapeutics.

[163]  Donna M Hepper,et al.  Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitors , 2013, Journal of cutaneous pathology.

[164]  M. Mahalingam,et al.  Cutaneous Adverse Events to Type I BRAF Inhibitors: An Analysis of Effects Associated with Each Inhibitor and Therapeutic Time Interval to Onset , 2013, American Journal of Clinical Dermatology.

[165]  L. Le,et al.  FLT3 inhibitor-induced neutrophilic dermatosis. , 2013, Blood.

[166]  M. Dómine,et al.  Acute and severe acne in a patient treated with bevacizumab , 2013, International journal of dermatology.

[167]  A. Hauschild,et al.  Analysis of dermatologic events in vemurafenib-treated patients with melanoma. , 2013, The oncologist.

[168]  A. Wysong,et al.  New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases. , 2013, JAMA dermatology.

[169]  J. Sosman,et al.  Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[170]  D. Rudmann.  On-target and Off-target-based Toxicologic Effects , 2013, Toxicologic pathology.

[171]  Yan-wen Yao,et al.  Skin Rash could Predict the Response to EGFR Tyrosine Kinase Inhibitor and the Prognosis for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis , 2013, PloS one.

[172]  O. Fiala,et al.  Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice. , 2013, Neoplasma.

[173]  G. Long,et al.  Cutaneous toxicities of RAF inhibitors. , 2013, The Lancet. Oncology.

[174]  E. Baudin,et al.  A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. , 2012, Archives of dermatology.

[175]  Christopher J. Miller,et al.  Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. , 2012, Journal of the American Academy of Dermatology.

[176]  S. Barni,et al.  Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. , 2012, Lung cancer.

[177]  K. Flaherty,et al.  Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.

[178]  A. Santoro,et al.  Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group. , 2012, Critical reviews in oncology/hematology.

[179]  C. Geest,et al.  The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. , 2012, Blood.

[180]  E. Baudin,et al.  Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[181]  J. Yi,et al.  OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[182]  M. Lacouture,et al.  The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis , 2012, Investigational New Drugs.

[183]  B. Oh,et al.  Epidermal Growth Factor Receptor Mutations in Colorectal Cancer Patients , 2011, Journal of the Korean Society of Coloproctology.

[184]  T. Cloughesy,et al.  AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme , 2011, Advances in therapy.

[185]  R. Udelsman,et al.  First use of intravenous chemotherapy cancer treatment: rectifying the record. , 2011, Journal of the American College of Surgeons.

[186]  A. Hauschild,et al.  Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors , 2011, International journal of dermatology.

[187]  C. Van Waes,et al.  EGFR–PI3K–AKT–mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy , 2011, Expert opinion on therapeutic targets.

[188]  M. Lacouture,et al.  Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) , 2011, Investigational New Drugs.

[189]  Lihong V Wang,et al.  Monoclonal Antibodies to Fibroblast Growth Factor Receptor 2 Effectively Inhibit Growth of Gastric Tumor Xenografts , 2010, Clinical Cancer Research.

[190]  G. Giaccone,et al.  Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib , 2010, Journal of experimental & clinical cancer research : CR.

[191]  H. Kong,et al.  Cutaneous pigmentation after photosensitivity induced by vandetanib therapy. , 2009, Archives of dermatology.

[192]  B. Yoder,et al.  An essential role for dermal primary cilia in hair follicle morphogenesis. , 2009, The Journal of investigative dermatology.

[193]  M. Lacouture,et al.  Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. , 2009, Clinical genitourinary cancer.

[194]  Chih-hsun Yang,et al.  Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[195]  C. Gridelli,et al.  Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting. , 2008, Critical reviews in oncology/hematology.

[196]  R. Siebert,et al.  Bullous sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib: interphase cytogenetic detection of BCR-ABL- positive lesional cells. , 2008, Archives of dermatology.

[197]  S. Pang,et al.  Hand‐foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy , 2007, The British journal of dermatology.

[198]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[199]  M. Lacouture,et al.  Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. , 2007, Skin therapy letter.

[200]  P. Keegan,et al.  FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. , 2007, The oncologist.

[201]  S. Yashar,et al.  Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. , 2007, Journal of the American Academy of Dermatology.

[202]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[203]  M. Lacouture.  Mechanisms of cutaneous toxicities to EGFR inhibitors , 2006, Nature Reviews Cancer.

[204]  M. Heffernan,et al.  Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib. , 2006, Journal of the American Academy of Dermatology.

[205]  N. Scheinfeld.  Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. , 2006, Journal of drugs in dermatology : JDD.

[206]  Huan Yang,et al.  The Akt/PKB pathway: molecular target for cancer drug discovery , 2005, Oncogene.

[207]  A. Lash,et al.  Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers , 2005, Clinical Cancer Research.

[208]  G. Mills,et al.  Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia. , 2005, Archives of dermatology.

[209]  Krister Wennerberg,et al.  The Ras superfamily at a glance , 2005, Journal of Cell Science.

[210]  Suk Woo Nam,et al.  PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas , 2005, Oncogene.

[211]  T. Ahmed,et al.  Sweet's syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking Imatinib Mesylate. , 2004, Leukemia research.

[212]  R. Schilsky,et al.  Cancer and Leukemia Group B 90206 , 2004, Clinical Cancer Research.

[213]  J. Testa,et al.  A Portrait of AKT Kinases: Human Cancer and Animal Models Depict a Family with Strong Individualities , 2004, Cancer biology & therapy.

[214]  C. Sawyers,et al.  Targeted cancer therapy , 2004, Nature.

[215]  J. Bartlett,et al.  Gene amplifications associated with the development of hormone-resistant prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[216]  J. Baselga,et al.  Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[217]  T. Wirth,et al.  Bruton's Tyrosine Kinase Is a Toll/Interleukin-1 Receptor Domain-binding Protein That Participates in Nuclear Factor κB Activation by Toll-like Receptor 4* , 2003, Journal of Biological Chemistry.

[218]  J. McCubrey,et al.  Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention , 2003, Leukemia.

[219]  B. Dörken,et al.  Imatinib‐induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia , 2002, European journal of haematology.

[220]  A. Halpern,et al.  Cutaneous side‐effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225 , 2001, The British journal of dermatology.

[221]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[222]  B. Trueb,et al.  Characterization of a novel protein (FGFRL1) from human cartilage related to FGF receptors. , 2000, Genomics.

[223]  Chen-Yang Shen,et al.  PIK3CA as an oncogene in cervical cancer , 2000, Oncogene.

[224]  Q. Gu,et al.  Activating Smoothened mutations in sporadic basal-cell carcinoma , 1998, Nature.

[225]  R. Myers,et al.  Human Homolog of patched, a Candidate Gene for the Basal Cell Nevus Syndrome , 1996, Science.

[226]  K. Isselbacher,et al.  Bruton tyrosine kinase is tyrosine phosphorylated and activated in pre-B lymphocytes and receptor-ligated B cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[227]  R. Lovering,et al.  Expression of the X-linked agammaglobulinemia gene, btk in B-cell acute lymphoblastic leukemia. , 1994, Leukemia.

[228]  John D Lambris,et al.  Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. , 1994, Journal of immunology.

[229]  J. V. van Dongen,et al.  The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages , 1993, European journal of immunology.

[230]  Ornella Parolini,et al.  Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia , 1993, Cell.

[231]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[232]  C. Nüsslein-Volhard,et al.  Mutations affecting segment number and polarity in Drosophila , 1980, Nature.

[233]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[234]  I. Todd,et al.  A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474 , 1971, British Journal of Cancer.

[235]  P. Nowell,et al.  A minute chromosome in human chronic granulocytic leukemia , 1960 .